Orbitrap Eclipse Tribrid Mass Spectrometer as a Regional Resource

Orbitrap Eclipse Tribrid 质谱仪作为区域资源

• 批准号: 10629013
• 负责人: Fuming Zhang
• 金额: $ 119.85万
• 依托单位: RENSSELAER POLYTECHNIC INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-05 至 2024-09-04
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10629013
• 关键词: 15 year old; Alzheimer' s Disease; Applications Grants; Biomanufacturing; Biomedical Engineering; Biophysics; Biotechnology; Capital; Cardiac; Cholesterol; Circadian Rhythms; Communities; Core Facility; Disease; Ensure; Experimental Designs; Funding; Human; Immune; Interdisciplinary Study; Investments; Lung; Maintenance; Malignant Neoplasms; Mass Spectrum Analysis; Minor; Molecular; New York; Parkinson Disease; Peer Review; Phosphorylation; Play; Policies; Polysaccharides; Proteomics; Publications; Radial; Renal glomerular disease; Request for Proposals; Research; Resources; Running; Sampling; Spinal cord injury; Technology; Time; United States National Institutes of Health; base; cost; experience; experimental study; human disease; instrument; instrumentation; mass spectrometer; microbiome; operation; programs; quantum; structural biology; success

7. Project Summary/Abstract This S10 Shared Instrumentation Grant Proposal requests funds to acquire an Orbitrap Eclipse Tribrid mass spectrometer (MS). This new Orbitrap will replace our current LTQ Orbitrap XL MS and the TSQ Quantum Ultra MS, both more than 15 years old. This strategic investment will save significant taxpayers’ moneys by replacing two old instruments with just one to reduce the cost of operation. At the same time, the unique capabilities of the Orbitrap Eclipse would greatly enhance the research topics which can be analyzed to meet the needs of our research community, including identification of PTMs including phosphorylation, analysis of glycans, and top- down proteomics. The new Orbitrap will be housed in the Proteomics core facility, in the Center for Biotechnology and Interdisciplinary Studies (CBIS), at RPI. If our proposal is funded, this advanced technology will be available to 30 research groups in the New York Capital Region. There are 20-NIH funded research groups participating in this proposal, nineteen of these are major users of the proposed instrumentation. Overall, this NIH-funded group is very strong with R01, R44, R37, R21, RF1, R35, R03 and accounts for 85% of the AUT. Currently an Orbitrap Eclipse Tribrid mass spectrometer is not available in a radius of 150 miles from RPI and will become an excellent resource in the NY Capital region and beyond. Many of the research programs in this proposal are related to bioengineering, structural biology, molecular biophysics and biomanufacturing. These programs are related to many human diseases, including Alzheimer’s disease, glomerular disease, spinal cord injury, lung recellularization, Parkinson’s disease, circadian rhythm, microbiome in human gut, and immune mechanisms/diseases, cardiac chirality, cancer, cholesterol levels, all of these projects are NIH funded. The user base spans from users with little experience in mass spectrometry that send samples to the facility and fully rely on the expertise of the Proteomics Core director, to highly experienced mass spectroscopists. Dr. Zagorevski will play a key role in designing experiments, running experiments and analyzing the results, making critical scientific contributions to the mass spectrometry field. Under his oversight, the Proteomics core is one of the most successful cores in CBIS with more than 90 peer-reviewed publications in the last 5 years. His outstanding expertise, well-established administration and maintenance policies, commitment to support both major and minor users, and affordable rates for both internal and external users will ensure success of this instrument as a regional resource.

7. 项目总结/摘要 此 S10 共享仪器拨款提案要求提供资金来购买 Orbitrap Eclipse Tribrid 质量 这种新型 Orbitrap 将取代我们当前的 LTQ Orbitrap XL MS 和 TSQ Quantum Ultra。 MS，均已超过 15 年。这项战略投资将通过更换来节省大量纳税人的钱。 两台旧仪器仅需一台即可降低运营成本，同时具有独特的功能。 Orbitrap Eclipse 将极大地增强可分析的研究主题，以满足我们的需求 研究社区，包括 PTM 的鉴定（包括磷酸化）、聚糖分析和顶部- 新的 Orbitrap 将位于生物技术中心的蛋白质组学核心设施中。 如果我们的提案得到资助，这项先进技术将可用。 纽约首都地区有 30 个研究小组 有 20 个 NIH 资助的研究小组参与其中。 在本提案中，其中 19 名是拟议仪器的主要用户。总体而言，该仪器由 NIH 资助。 集团非常强大，有 R01、R44、R37、R21、RF1、R35、R03，占 AUT 的 85%。 Orbitrap Eclipse Tribrid 质谱仪在距 RPI 150 英里半径范围内不可用，将成为 本提案中的许多研究项目都是纽约首都地区及其他地区的优秀资源。 与生物工程、结构生物学、分子生物物理学和生物制造相关。 与许多人类疾病有关，包括阿尔茨海默病、肾小球疾病、脊髓损伤、肺病 再细胞化、帕金森病、昼夜节律、人体肠道微生物组和免疫 机制/疾病、心脏手性、癌症、胆固醇水平，所有这些项目都是 NIH 资助的。 基础跨越在质谱方面缺乏经验的用户，他们将样品发送到设施并完全依赖 蛋白质组学核心主任的专业知识，经验丰富的质谱专家 Zagorevski 博士。 将在设计实验、运行实验和分析结果方面发挥关键作用，使关键 在他的监督下，蛋白质组学核心是对质谱领域的科学贡献之一。 CBIS 中最成功的核心，在过去 5 年中发表了 90 多篇同行评审出版物。 专业知识、完善的管理和维护政策、支持主要和 少数用户以及内部和外部用户都可以承受的价格将确保该工具作为一个工具的成功 区域资源。